Represented ALPHAEON Corporation in its purchase of shares of Series A Preferred Stock from Zelegent, Inc. to lead Zelgent’s Series A financing. Zelegent is a medical technology company that is developing, and plans to manufacture and market, innovative tools for physicians who treat sleep disorders. Zelegent’s mission is to develop and commercialize a novel minimally-invasive advanced medical device to be used by sleep specialist otolaryngologists to treat snoring by shortening, suspending and stiffening the patient’s soft palate, the source of most snoring.
ALPHAEON is a social commerce company with the goal of transforming self-pay healthcare by leveraging the power of its professional network of physician specialists to drive lifestyle healthcare advancements, and improve patient experiences and outcomes in the wellness, beauty and performance sectors. Read the press release.
Jeff Estes represented ALPHAEON in the transaction.